| Year |
Citation |
Score |
| 2013 |
Lin WH, Vilalta A, Adams RJ, Rolland A, Sullivan SM, Griffin DE. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. Journal of Virology. 87: 6560-8. PMID 23552419 DOI: 10.1128/Jvi.00635-13 |
0.425 |
|
| 2009 |
Vilalta A, Shlapobersky M, Wei Q, Planchon R, Rolland A, Sullivan S. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA. Vaccine. 27: 7409-17. PMID 19735757 DOI: 10.1016/J.Vaccine.2009.08.075 |
0.45 |
|
| 2009 |
Shlapobersky M, Wei Q, Sullivan S, Vilalta A. Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters. Vaccine. 27: 6404-10. PMID 19607952 DOI: 10.1016/J.Vaccine.2009.06.087 |
0.343 |
|
| 2009 |
Hartikka J, Bozoukova V, Yang CK, Ye M, Rusalov D, Shlapobersky M, Vilalta A, Wei Q, Rolland A, Smith LR. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine. 27: 6399-403. PMID 19552895 DOI: 10.1016/J.Vaccine.2009.06.014 |
0.384 |
|
| 2009 |
Muller WJ, Dong L, Vilalta A, Byrd B, Wilhelm KM, McClurkan CL, Margalith M, Liu C, Kaslow D, Sidney J, Sette A, Koelle DM. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. The Journal of General Virology. 90: 1153-63. PMID 19264627 DOI: 10.1099/Vir.0.008771-0 |
0.391 |
|
| 2008 |
Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clinical and Vaccine Immunology : Cvi. 15: 1214-21. PMID 18524884 DOI: 10.1128/Cvi.00120-08 |
0.389 |
|
| 2007 |
Vilalta A, Jimenez G, Rusalov D, Planchon R, Lalor P, Carner K, Chaplin JA, Komai M, Manthorpe M, Kaslow DC, Rolland A. Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge. Human Gene Therapy. 18: 763-71. PMID 17705698 DOI: 10.1089/Hum.2007.009 |
0.378 |
|
| 2006 |
Leamy VL, Martin T, Mahajan R, Vilalta A, Rusalov D, Hartikka J, Bozoukova V, Hall KD, Morrow J, Rolland AP, Kaslow DC, Lalor PA. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines Human Vaccines. 2: 113-118. PMID 17012905 DOI: 10.4161/Hv.2836 |
0.352 |
|
| 2006 |
Margalith M, Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genetic Vaccines and Therapy. 4: 2. PMID 16480501 DOI: 10.1186/1479-0556-4-2 |
0.364 |
|
| 2005 |
Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, Bozoukova V, Lalor P, Hall K, Kaslow DC, Rolland A. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Human Gene Therapy. 16: 1151-6. PMID 16218776 DOI: 10.1089/Hum.2005.16.1151 |
0.401 |
|
| 2005 |
Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow DC. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Human Gene Therapy. 16: 1143-50. PMID 16218775 DOI: 10.1089/Hum.2005.16.1143 |
0.381 |
|
| 2004 |
Vilalta A, Margalith M, Evans T, Kaslow DC, Hobart P. 486. Plasmid DNA constructs expressing SARS-CoV antigens are immunogenic in mice and rabbits Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.392 |
0.416 |
|
| 2002 |
Vilalta A, Whitlow V, Martin T. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Analytical Biochemistry. 301: 151-3. PMID 11811979 DOI: 10.1006/Abio.2001.5480 |
0.301 |
|
| 2001 |
Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, Hedstrom R, Rogers WO, Kumar S, Hoffman SL, Norman JA. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine Gene Therapy. 8: 1011-1023. PMID 11438836 DOI: 10.1038/Sj.Gt.3301491 |
0.401 |
|
| 2001 |
Vilalta A, Wu D, Margalith M, Hobart P. Rabbit EPO gene and cDNA: expression of rabbit EPO after intramuscular injection of pDNA. Biochemical and Biophysical Research Communications. 284: 823-827. PMID 11396976 DOI: 10.1006/Bbrc.2001.5028 |
0.412 |
|
| 2000 |
Willoughby DA, Vilalta A, Oshima RG. An Alu element from the K18 gene confers position-independent expression in transgenic mice. The Journal of Biological Chemistry. 275: 759-68. PMID 10625605 DOI: 10.1074/Jbc.275.2.759 |
0.361 |
|
| 1997 |
Vilalta A, Trivedi A, Wang Z, Roeder RG, Johnson DL. An RNA polymerase III-defective mutation in TATA-binding protein disrupts its interaction with a transcription factor IIIB subunit in drosophila cells. The Journal of Biological Chemistry. 272: 18087-92. PMID 9218440 DOI: 10.1074/Jbc.272.29.18087 |
0.527 |
|
| 1997 |
Trivedi A, Vilalta A, Gopalan S, Johnson DL. TATA-binding protein is limiting for both TATA-containing and TATA-lacking RNA polymerase III promoters in Drosophila cells. Molecular and Cellular Biology. 16: 6909-16. PMID 8943346 DOI: 10.1128/Mcb.16.12.6909 |
0.519 |
|
| 1994 |
Garber ME, Vilalta A, Johnson DL. Induction of Drosophila RNA polymerase III gene expression by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) is mediated by transcription factor IIIB. Molecular and Cellular Biology. 14: 339-47. PMID 8264601 DOI: 10.1128/Mcb.14.1.339 |
0.536 |
|
| 1993 |
Vilalta A, Donovan D, Wood L, Vogeli G, Yang DCH. Cloning, sequencing and expression of a cDNA encoding mammalian valyl-tRNA synthetase Gene. 123: 181-186. PMID 8428657 DOI: 10.1016/0378-1119(93)90122-J |
0.324 |
|
| Show low-probability matches. |